<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672867</url>
  </required_header>
  <id_info>
    <org_study_id>L-FMAU-309</org_study_id>
    <nct_id>NCT00672867</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B</brief_title>
  <official_title>A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and antiviral activity of Clevudine Versus&#xD;
      Adefovir dipivoxil in patients with LC-B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA below 12 IU/mL by Real-Time PCR</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA from the baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg loss and/or seroconversion</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Patients With LC-B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine</intervention_name>
    <description>30mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Levovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>10mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is 18 years and older.&#xD;
&#xD;
          2. 5 ≦ Child-Pugh score ≦ 12&#xD;
&#xD;
          3. Patient is HBV DNA positive with DNA levels ≥ 1 x 10(4) copies/mL within 30 days of&#xD;
             baseline.&#xD;
&#xD;
          4. Patient is documented to be HBsAg positive for &gt; 6 months.&#xD;
&#xD;
          5. Patient is HBeAg positive or negative.&#xD;
&#xD;
          6. Patient has ALT or AST levels which are in the range of &gt; 1 x ULN and &lt; 15 X ULN&#xD;
&#xD;
          7. Patient with liver cirrhosis diagnosed by imaging study within 1 year or clinical&#xD;
             evidence of portal hypertension&#xD;
&#xD;
          8. Life expectancy of at least 12 months&#xD;
&#xD;
          9. Female patient with a negative urine(Beta-HCG) pregnancy test taken within 14 days of&#xD;
             starting therapy.&#xD;
&#xD;
         10. Patient who is able to give written informed consent prior to study start and to&#xD;
             comply with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or&#xD;
             corticosteroid therapy.&#xD;
&#xD;
          2. Previous treatment with interferon must have ended at least 6 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
          3. Patients previously treated with clevudine, entecavir, lamivudine, adefovir,&#xD;
             telbivudine or any other investigational nucleoside for HBV infection.&#xD;
&#xD;
          4. Patient is coinfected with HCV, HDV or HIV.&#xD;
&#xD;
          5. Patient with clinical evidence of hepatocellular carcinoma&#xD;
&#xD;
          6. Patient has alpha-fetoprotein &gt; 400ng/mL.&#xD;
&#xD;
          7. Patient has Hemoglobin &lt;8g/dL (Male), 7.5g/dL (Female) or WBC &lt;1,500mm3 or Neutrophils&#xD;
             &lt;500/mm3 or Platelet count &lt;30,000/mm3.&#xD;
&#xD;
          8. Patient is pregnant or breast-feeding.&#xD;
&#xD;
          9. Patient is unwilling to use an &quot;effective&quot; method of contraception during the study&#xD;
             and for up to 3 months after the use of study drug ceases.&#xD;
&#xD;
         10. Patient has a clinically relevant history of abuse of alcohol or drugs.&#xD;
&#xD;
         11. Patient with previous liver transplantation&#xD;
&#xD;
         12. Patient has a significant immunocompromised, gastrointestinal, renal, hematological,&#xD;
             psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone,&#xD;
             neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness&#xD;
             that in the investigator's opinion might interfere with therapy.&#xD;
&#xD;
         13. Patient has creatinine clearance less than 60mL/min as estimated by the following&#xD;
             formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note:&#xD;
             multiply estimates by 0.85 for women]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

